Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.69 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | GGT1 | P19440 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332285 | 1.00 | PTGS2 (0.69) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL30269568 | 1.00 | PTGS2 (0.69) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| Acetone SCHEMBL28889942 | 0.98 | PTGS2 (0.67) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL3814657 | 0.93 | HSD17B10 (0.73) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL13086585 | 0.85 | PTGS2 (0.65) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL11017487 | 0.83 | PTGS2 (0.74) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL189443 | 0.83 | PTGS2 (0.74) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL11050544 | 0.83 | KDM4E (0.74) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL415898 | 0.83 | MAPK1 (0.72) | PTGS2KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL414201 | 0.83 | ACHE (0.56) | PTGS2KDM4EHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954744-B | Aspirin-sulfonamide hybrid, and preparation method and application thereof | 宁夏大学 | 2026-05-15 | — | — | CN | claimed |
| CN-119954744-A | Aspirin-sulfonamide hybrid, and preparation method and application thereof | 宁夏大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119874638-A | Aspirin-dithiocarbamic acid ester hybrid and preparation method and application thereof | 宁夏大学 | 2025-04-25 | — | — | CN | claimed |
| US-20240417381-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NITAZOXANIDE AND INTERMEDIATES THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED (IN) | 2024-12-19 | — | — | US | claimed |
| CN-118403070-A | Heparin-aspirin compound, preparation and application | 中国科学院理化技术研究所 | 2024-07-30 | — | — | CN | claimed |
| CN-118164871-A | N-ester-2-acetylsalicylamide compound and preparation method and application thereof | 湖南科技大学 | 2024-06-11 | — | — | CN | claimed |
| CN-118125973-A | Water-soluble fluorescent probe for enhancing aggregation-induced emission performance through rotor structure, and preparation method and application thereof | 新乡医学院 | 2024-06-04 | — | — | CN | claimed |
| CN-117820200-A | Heterobivalent compound taking piperidinoindenone-salicylic acid as parent, and preparation method and application thereof | 合肥工业大学 | 2024-04-05 | — | — | CN | claimed |
| CN-115154401-B | Anti-inflammatory and soothing emulsion and preparation method thereof | 武汉诺安药业有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116333038-A | Aspirin derivative, preparation method and application thereof in preventing cardiovascular and cerebrovascular diseases | 湖北南博生物工程有限公司 | 2023-06-27 | — | — | CN | claimed |
| EP-0639559-A1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM AND HAAS COMPANY (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0251039-B1 | ESTERS OF SALSALATE WITH GUAIACOL, FOR TREATING PHLOGISTIC BRONCHOPNEUMOPATHIES | FINTECO Srl (IT) | 1991-09-18 | — | — | EP | claimed |
| EP-0272223-B1 | 4-OXO-1,3-BENZODIOXANE DERIVATIVE | FARMACEUTICI CABER S.p.A. (IT) | 1991-05-29 | — | — | EP | claimed |
| US-4762945-A | PEROXIDATION OF ACETYLSALICYLOYL CHLORIDE IN TETRAHYDROFURAN AND DICHLOROMETHANE | USV PHARMACEUTICAL CORPORATION (US) | 1988-08-09 | — | — | US | claimed |
| US-4743704-A | Esters of salsalate with guaiacol, for treating phlogistic bronchopneumopathies | FINTECO SRL (IT) | 1988-05-10 | — | — | US | claimed |
| EP-0202305-A1 | CARBON HYDRATE ESTERS OF ACETYLSALICYLIC ACID, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS | Evidenzbüro österreichischer Zuckerfabriken Gesellschaft m.b.H. (AT) | 1986-11-26 | — | — | EP | claimed |
| WO-1986003206-A1 | CARBON HYDRATE ESTERS OF ACETYLSALICYLIC ACID, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS | EVIDENZBÜRO ÖSTERREICHISCHER ZUCKERFABRIKEN GESELL (AT) | 1986-06-05 | — | — | WO | claimed |
| EP-0080609-B1 | NOVEL COMPOUND HAVING ANALGESIC, ANTIINFLAMMATORY AND ANTIPYRETIC ACTIVITY, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RESEARCH S.r.l. (IT) | 1985-08-21 | — | — | EP | claimed |
| EP-0080229-B1 | SALICYLIC DERIVATIVES OF N-ACETYLCYSTEINE | Pietro Isnardi & C. Spa (IT) | 1985-03-13 | — | — | EP | claimed |
| US-4046887-A | Glycerides with anti-inflammatory properties | ABBOTT LABORATORIES (US) | 1977-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417381-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NITAZOXANIDE AND INTERMEDIATES THEREOF | NIT2, NUDT1, QDPR | PTGS2 576/4885KDM4E 226/4885HSD17B10 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.